tiprankstipranks
Avalyn Pharma Inc (AVLN)
NASDAQ:AVLN
US Market
AVLN
Avalyn Pharma Inc
RESEARCH TOOLSreports

Avalyn Pharma Inc (AVLN) Price & Analysis

7 Followers

AVLN Stock Chart & Stats

$37.13
--
Market closed
$37.13
--
Day’s Range― - ―
52-Week Range$24.15 - $40.17
Previous CloseN/A
VolumeN/A
Average Volume (3M)931.19K
Market Cap
$1.70B
Enterprise Value$1.12K
Total Cash (Recent Filing)$352.43M
Total Debt (Recent Filing)$17.11M
Price to Earnings (P/E)―
Beta1.48
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding44,333,096
10 Day Avg. Volume383,220
30 Day Avg. Volume931,186
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-5.17
Price to Sales (P/S)0.00
P/FCF Ratio-15.07
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$53.33
Price Target Upside43.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A

Avalyn Pharma Inc News

One new option listing and two option delistings on August 21st
One new option listing and two option delistings on August 21st
New option listings for August 21st include Avalyn Pharma Inc (AVLN). Option delistings effective August 21st include Liberty...
2d ago
AVLN
One new option listing and two option delistings on August 21st
One new option listing and two option delistings on August 21st
New option listings for August 21st include Avalyn Pharma Inc (AVLN). Option delistings effective August 21st include Liberty...
2d ago
AVLN
Avalyn Pharma price target raised to $57 from $53 at Morgan Stanley
Avalyn Pharma price target raised to $57 from $53 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Avalyn Pharma (AVLN) to $57 from $53 and keeps an...
7d ago
AVLN
Avalyn Pharma completes target enrollment in MIST trial
Avalyn Pharma completes target enrollment in MIST trial
Avalyn Pharma (AVLN) announced that it has completed target enrollment of 375 patients in the Phase 2b MIST...
2M ago
AVLN
Opening Day: SpaceX submits S-1 for Nasdaq IPO
Opening Day: SpaceX submits S-1 for Nasdaq IPO
SpaceX and OpenAI are moving toward blockbuster public debuts, with SpaceX formally filing its Form S 1 to...
3M ago
PS
LZO
Avalyn Pharma initiated with an Outperform at Evercore ISI
Avalyn Pharma initiated with an Outperform at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner initiated coverage of Avalyn Pharma (AVLN) with an Outperform rating and $51 price...
3M ago
AVLN
Avalyn Pharma initiated with an Overweight at Morgan Stanley
Avalyn Pharma initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Avalyn Pharma (AVLN) with an Overweight rating and $53 price target The company...
3M ago
AVLN
Avalyn Pharma initiated with a Buy at Guggenheim
Avalyn Pharma initiated with a Buy at Guggenheim
Guggenheim analyst Seamus Fernandez initiated coverage of Avalyn Pharma (AVLN) with a Buy rating and $80 price target...
3M ago
AVLN
Analyst Reiterates Buy on Avalyn, Citing Inhaled IPF/PPF Pipeline and Multiple Revenue Streams to Support $52 Price Target
Roger Song, an analyst from Jefferies, has initiated a new Buy rating on Avalyn Pharma Inc (AVLN). Roger...
3M ago
AVLN
Avalyn Pharma initiated with a Buy at Jefferies
Avalyn Pharma initiated with a Buy at Jefferies
Jefferies initiated coverage of Avalyn Pharma (AVLN) with a Buy rating and $52 price target The firm says...
3M ago
AVLN

AVLN FAQ

What was Avalyn Pharma Inc’s price range in the past 12 months?
Avalyn Pharma Inc lowest stock price was $24.15 and its highest was $40.17 in the past 12 months.
    What is Avalyn Pharma Inc’s market cap?
    Avalyn Pharma Inc’s market cap is $1.70B.
      When is Avalyn Pharma Inc’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Avalyn Pharma Inc’s earnings last quarter?
      Currently, no data Available
      Is Avalyn Pharma Inc overvalued?
      According to Wall Street analysts Avalyn Pharma Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Avalyn Pharma Inc pay dividends?
        Avalyn Pharma Inc does not currently pay dividends.
        What is Avalyn Pharma Inc’s EPS estimate?
        Avalyn Pharma Inc’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Avalyn Pharma Inc have?
        Avalyn Pharma Inc has 44,333,096 shares outstanding.
          What happened to Avalyn Pharma Inc’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Avalyn Pharma Inc?
          Currently, no hedge funds are holding shares in AVLN
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Avalyn Pharma Inc Stock Smart Score

            6
            Neutral
            1
            2
            3
            4
            5
            6
            7
            8
            9
            10

            Analyst Consensus

            Strong Buy
            Average Price Target:
            $53.33 (43.64% Upside)

            News Sentiment

            Very Bullish
            Bullish news 100%
            Bearish news 0%
            Top Smart Score Stocks >

            Company Description

            Avalyn Pharma Inc

            Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.

            Avalyn Pharma Inc (AVLN) Earnings & Revenues

            Historic Earnings Reports

            AVLN Stock 12 Month Forecast

            Average Price Target

            $53.33
            ▲(43.64% Upside)
            {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","58":"$58","33.25":"$33.3","41.5":"$41.5","49.75":"$49.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$57.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53.333333333333336,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$53.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$51.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,33.25,41.5,49.75,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.79,30.96,33.129999999999995,35.3,37.47,39.64,41.81,43.98,46.15,48.32,50.489999999999995,52.66,54.83,{"y":57,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.79,30.677948717948716,32.56589743589743,34.45384615384616,36.341794871794875,38.22974358974359,40.11769230769231,42.005641025641026,43.89358974358974,45.78153846153846,47.66948717948718,49.557435897435894,51.44538461538462,{"y":53.333333333333336,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.79,30.498461538461537,32.206923076923076,33.91538461538462,35.62384615384615,37.332307692307694,39.04076923076923,40.74923076923077,42.457692307692305,44.16615384615385,45.87461538461538,47.58307692307692,49.291538461538465,{"y":51,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":29.49,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.49,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.49,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.49,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.49,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.49,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.49,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.49,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.49,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.84,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.66,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.17,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.79,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
            Detailed Analyst Forecast >
            Similar Stocks
            Company
            Price & Change
            Follow
            BGMS
            Bio Green Med Solution
            ―
            ―
            KYNB
            Kyntra Bio
            ―
            ―
            ONC
            BeOne Medicines
            ―
            ―
            RNTX
            Rein Therapeutics
            ―
            ―
            NEUP
            Neuphoria Therapeutics
            ―
            ―
            Compare AVLN Stocks >

            Ownership Overview

            29.18%65.99%1.05%
            29.18% Insiders
            ― Mutual Funds
            65.99% Other Institutional Investors
            1.05% Public Companies and
            Individual Investors
            Detailed Ownership Overview >
            Popular Stocks